Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
A search of the Pubmed database for the word curcumin yields 16,818 studies spanning health topics from
Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe, effective and relatively inexpensive.
Whether for the blood cancer called multiple myeloma or side effects and possible secondary cancers, curcumin is a wonder drug.
I have read posts about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive therapy.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
I consult the independent evaluation service Consumerlab.com frequently. For one low annual payment, I can read about and evaluate all of the nutritional supplements that I take.
The challenge for every myeloma patient is to achieve the deepest, longest remission possible while sustaining the least amount of collateral damage (side effects) possible. Numerous studies document the anti-MM and integrative efficacy of curcumin.
This link is to the Google search page for “curcumin in myeloma.” Whether it is an article authored by Pat Killingsworth or Margaret from Margaret’s Corner, or PubMed, curcumin is documented to be both cytotoxic to myeloma in addition to being “integrative” or enhancing the action of Velcade, Revlimid, and Thalidomide.
A common question asked by multiple myeloma patients considering supplementing with curcumin is about the daily dose.
Unfortunately, I have several possible answers:
The post above focuses on curcumin and my cancer, multiple myeloma. But what about curcumin as an evidence-based but non-toxic therapy for other cancers, other health challenges?
The challenge with cancer is that conventional oncology gives patients lots of toxic therapy in hopes of one or more remissions. The challenge with toxicity is that it causes lots of damage to the human body.
I take curcumin in an effort to reduce my risk os any and all therapy-related health issues.
Scroll down the page, post a question or comment and I will reply to you ASAP.
“Curcumin has been credited with a wide spectrum of pharmacological properties for the prevention and treatment of several chronic diseases such as
However, due to its weak solubility and bioavailability, it has limited potential as an oral medication. Numerous factors including low water solubility, poor intestinal permeability, instability at alkaline pH, and fast metabolism contribute to curcumin’s limited oral bioavailability. In order to improve its oral bioavailability, different formulation techniques such as coadministration with piperine, incorporation into micelles, micro/nanoemulsions, nanoparticles, liposomes, solid dispersions, spray drying, and noncovalent complex formation with galactomannosides have been investigated with in vitro cell culture models, in vivo animal models, and humans.
In the current study, we extensively reviewed clinical trials on various generations of curcumin formulations and their safety and efficacy in the treatment of many diseases. We also summarized the dose, duration, and mechanism of action of these formulations. We have also critically reviewed the advantages and limitations of each of these formulations compared to various placebo and/or available standard care therapies for these ailments.
Background: CU, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model…
Conclusion: CU exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.
“Multiple myeloma (MM), a plasma cell malignancy, remains incurable despite the development of new therapies. CU anti-tumor effects were previously characterized in multiple myeloma, however only few MM cell lines were included in these studies.
Since myeloma is a heterogeneous disease it is important to address the impact of myeloma molecular heterogeneity in CU cell death induction.
In the present study, a large panel of human myeloma cell lines (HMCLs) (n = 29), representing the main molecular MM subgroups, was screened for CU sensitivity. We observed that CU cell death induction was heterogeneous, of note 16 HMCLs were highly sensitive to CU (LD50 < 20.5 μM), 6 HMCLs exhibited intermediate LD50 values (20.5 μM ≤ LD50 < 32.2 μM) and only 7 HMCLs were weakly sensitive (35 < LD50 < 56 μM).
Cell lines harboring the t(11;14) translocation were less sensitive (median LD50 32.9 μM) than non-t(11;14) (median LD50 17.9 μM), which included poor prognosis t(4;14) and t(14;16) cells.
Interestingly, CU sensitivity was not dependent on TP53 status. For the first time we showed that primary myeloma cells were also sensitive, even those displaying del(17p), another poor prognosis factor. We also unravel the contribution of anti-apoptotic Bcl-2 family molecules in CU response.
We found that down-regulation of Mcl-1, an essential MM survival factor, was associated with CU-induced cell death and its knockdown sensitized myeloma cells to CU, highlighting Mcl-1 as an important target for CU-induced apoptosis. Altogether, these results support clinical trials including CU in association with standard therapy.”